Cargando…
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates
We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL (pro)) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Compariso...
Autores principales: | Chen, Yu Wai, Yiu, Chin-Pang Bennu, Wong, Kwok-Yin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062204/ https://www.ncbi.nlm.nih.gov/pubmed/32194944 http://dx.doi.org/10.12688/f1000research.22457.2 |
Ejemplares similares
-
Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022) -
Virtual screening on the web for drug repurposing: a primer
por: Chen, Yu Wai, et al.
Publicado: (2021) -
Inhibition of the SARS-CoV-2 3CL(pro) main protease by plant polyphenols
por: Bahun, Miha, et al.
Publicado: (2022) -
The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL(pro) In Vitro
por: Eberle, Raphael J., et al.
Publicado: (2021) -
Inhibition of SARS-CoV 3CL protease by flavonoids
por: Jo, Seri, et al.
Publicado: (2019)